News | May 08, 2026
Lupin Q4 FY26 PBT jumps 115% to Rs 19,280 million
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
Hair care & quick commerce shine
The standout story remains Wegovy, particularly its new oral formulation
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
The company secured new accounts, including ACCESS-PVI trial sites, and aims to strengthen global commercialization efforts
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
With over 30 years of pharmaceutical industry experience, Ponnusamy will lead Alembic’s animal health business strategy, market expansion, and operational growth initiatives
Subscribe To Our Newsletter & Stay Updated
